Bain helps push Affinivax to next stage with $120M round, as PhII data loom on a lead effort to do something new in vaccines
Affinivax CEO Steven Brugger has always looked for unconventional ways to go about the business of vaccine R&D. The Gates Foundation put up a lot of the initial seed cash in 2014 and an early alliance with Astellas paid the bills — which now covers a staff of about 70 in Cambridge, MA.
When the pandemic hit, Brugger’s team kept the lab going by reducing and distancing the numbers inside while moving to a 7-day schedule.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.